Literature DB >> 31377590

Wogonin attenuates liver fibrosis via regulating hepatic stellate cell activation and apoptosis.

Xiao-Sa Du1, Hai-Di Li1, Xiao-Juan Yang1, Juan-Juan Li1, Jie-Jie Xu1, Yu Chen1, Qing-Qing Xu1, Lei Yang1, Chang-Sheng He1, Cheng Huang1, Xiao-Ming Meng1, Jun Li2.   

Abstract

Liver fibrosis is the representative features of liver chronic inflammation and the characteristic of early cirrhosis. To date, effective therapy for liver fibrosis is lacking. Recently, Traditional Chinese Medicine (TCM) has attracted increasing attention due to its wide pharmacological effects and more uses in clinical. Wogonin, as one major active constituent of Scutellaria radix, has been reported it plays an important role in anti-inflammatory, anti-cancer, anti-viral, anti-angiogenesis, anti-oxidant and neuro-protective effects. However, the anti-fibrotic effect of wogonin is never covered in liver. In this study, we evaluated the protect effect of wogonin in liver fibrosis. Wogonin significantly attenuated liver fibrosis both in CCl4-induced mice and TGF-β1 activated HSCs. Meanwhile, wogonin can enhances apoptosis of TGF-β1 activated HSC-T6 cell from rat and LX-2 cell from human detected by flow cytometry. Additionally, wogonin can largely enhances cle-caspase3, cle-caspase9 expression and the ratio of Bax/Bcl-2 in T6 cells. Pro-apoptosis effect of wogonin in vivo was further verified in situ. In conclusion, wogonin can attenuate liver fibrosis via regulating the activation and apoptosis of hepatic stellate cells, and may be an effective drug to treat and prevent liver fibrosis.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Apoptosis; Hepatic stellate cells (HSCs); Liver fibrosis; Wogonin

Mesh:

Substances:

Year:  2019        PMID: 31377590     DOI: 10.1016/j.intimp.2019.05.056

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  12 in total

1.  Anti-liver fibrosis effects of the total flavonoids of litchi semen on CCl4-induced liver fibrosis in rats associated with the upregulation of retinol metabolism.

Authors:  Jiongyi Yan; Yinyi Feng; Xuewan Fang; Xiaojuan Cui; Xing Xia; Fang Li; Weisheng Luo; Jianqin Liang; Jianfang Feng; Kai Yu
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

2.  Didymin Ameliorates Liver Fibrosis by Alleviating Endoplasmic Reticulum Stress and Glycerophospholipid Metabolism: Based on Transcriptomics and Metabolomics.

Authors:  Yan Li; Cuiyu Li; Yuhua Xiong; Bin Fang; Xing Lin; Quanfang Huang
Journal:  Drug Des Devel Ther       Date:  2022-06-07       Impact factor: 4.319

3.  Analysis of the mechanism of Shufeng Jiedu capsule prevention and treatment for COVID-19 by network pharmacology tools.

Authors:  Haijun Xiong; Zhaowei Dong; Guanhua Lou; Qingxia Gan; Jin Wang; Qinwan Huang
Journal:  Eur J Integr Med       Date:  2020-10-30       Impact factor: 1.314

4.  Identification of Differential Expression Cytokines in Hemolysis, Elevated Liver Enzymes, and Low Platelet Syndrome by Proteome Microarray Analysis and Further Verification.

Authors:  Suya Kang; Liping Zhou; Yun Wang; Hui Li; Hong Zhang
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

5.  Shibi Tea (Adinandra nitida) and Camellianin A Alleviate CCl4-Induced Liver Injury in C57BL-6J Mice by Attenuation of Oxidative Stress, Inflammation, and Apoptosis.

Authors:  Ruohong Chen; Yingyi Lian; Shuai Wen; Qiuhua Li; Lingli Sun; Xingfei Lai; Zhenbiao Zhang; Junquan Zhu; Linsong Tang; Ji Xuan; Erdong Yuan; Shili Sun
Journal:  Nutrients       Date:  2022-07-24       Impact factor: 6.706

6.  Scutellaria barbata D. Don Inhibits the Main Proteases (Mpro and TMPRSS2) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.

Authors:  Sheng-Teng Huang; Yeh Chen; Wei-Chao Chang; Hsiao-Fan Chen; Hsiang-Chun Lai; Yu-Chun Lin; Wei-Jan Wang; Yu-Chuan Wang; Chia-Shin Yang; Shao-Chun Wang; Mien-Chie Hung
Journal:  Viruses       Date:  2021-05-02       Impact factor: 5.048

7.  Wogonin Alleviates Kidney Tubular Epithelial Injury in Diabetic Nephropathy by Inhibiting PI3K/Akt/NF-κB Signaling Pathways.

Authors:  Lei Lei; Jing Zhao; Xue-Qi Liu; Juan Chen; Xiang-Ming Qi; Ling-Ling Xia; Yong-Gui Wu
Journal:  Drug Des Devel Ther       Date:  2021-07-16       Impact factor: 4.162

Review 8.  The Therapeutic Potential of Wogonin Observed in Preclinical Studies.

Authors:  Javad Sharifi-Rad; Jesús Herrera-Bravo; Luis A Salazar; Shabnum Shaheen; Seyed Abdulmajid Ayatollahi; Farzad Kobarfard; Muhammad Imran; Ali Imran; Luísa Custódio; María Dolores López; Mauricio Schoebitz; Miquel Martorell; Manoj Kumar; Hafiz Ansar Rasul Suleria; William C Cho
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-15       Impact factor: 2.629

9.  Current biological and pharmacological updates on wogonin.

Authors:  Sarita Rawat; Gaurav Gupta; Sachchidanand Pathak; Santosh Kumar Singh; Himmat Singh; Anurag Mishra; Ritu Gilhotra; Alaa A A Aljabali; Harish Dureja; Murtaza M Tambuwala; Dinesh K Chellappan; Kamal Dua
Journal:  EXCLI J       Date:  2020-05-13       Impact factor: 4.068

Review 10.  Traditional Chinese Medicine in nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives.

Authors:  Xianmin Dai; Jiayi Feng; Yi Chen; Si Huang; Xiaofei Shi; Xia Liu; Yang Sun
Journal:  Chin Med       Date:  2021-08-03       Impact factor: 5.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.